Sulfation of 4-hydroxy toremifene: Individual variability, isoform specificity, and contribution to toremifene pharmacogenomics

Drug Metabolism and Disposition

Volumn 40, Issue 6, 2012, Pages 1210-1215

  Edavana, Vineetha Koroth ^a   Dhakal, Ishwori B ^a   Yu, Xinfeng ^a   Williams, Suzanne ^a   Kadlubar, Susan ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 NAPHTHOL; 2,6 DICHLORO 4 NITROPHENOL; 4 HYDROXYTOREMIFENE; ESTRADIOL; SULFOTRANSFERASE; SULFOTRANSFERASE 1A1; SULFOTRANSFERASE 1E1; TOREMIFENE; UNCLASSIFIED DRUG;

AGED; ARTICLE; CATALYSIS; CHILD; CONTROLLED STUDY; DRUG SPECIFICITY; DRUG SULFATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; FEMALE; GENE DOSAGE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CYTOSOL; MALE; MICHAELIS MENTEN KINETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARYLSULFOTRANSFERASE; CHILD; FEMALE; GENETIC VARIATION; HUMANS; LIVER; MALE; MIDDLE AGED; PHARMACOGENETICS; PROTEIN ISOFORMS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TOREMIFENE; YOUNG ADULT;

EID: 84862074475     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.044040     Document Type: Article

References (29)

1. Berthou F, Dreano Y, Belloc C, Kangas L, Gautier JC, and Beaune P (1994) Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes. Biochem Pharmacol 47:1883-1895. (Pubitemid 24172859)
2. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
3. Buzdar AU and Hortobagyi GN (1998) Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy. J Clin Oncol 16:348-353. (Pubitemid 28041619)
4. Chen G, Yin S, Maiti S, and Shao X (2002) 4-Hydroxytamoxifen sulfation metabolism. J Biochem Mol Toxicol 16:279-285.
5. Crewe HK, Notley LM, Wunsch RM, Lennard MS, and Gillam EM (2002) Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos 30:869-874. (Pubitemid 34815415)
6. Falany CN, Krasnykh V, and Falany JL (1995) Bacterial expression and characterization of a cDNA for human liver estrogen sulfotransferase. J Steroid Biochem Mol Biol 52:529-539.
7. Frame LT, Ozawa S, Nowell SA, Chou HC, DeLongchamp RR, Doerge DR, Lang NP, and Kadlubar FF (2000) A simple colorimetric assay for phenotyping the major human thermostable phenol sulfotransferase (SULT1A1) using platelet cytosols. Drug Metab Dispos 28: 1063-1068. (Pubitemid 30660361)
8. Gershanovich M, Hayes DF, Ellmén J, and Vuorinen J (1997) High-dose toremifene vs tamoxifen in postmenopausal advanced breast cancer. Oncology (Williston Park) 11:29-36. (Pubitemid 27262887)
9. Hard GC, Iatropoulos MJ, Jordan K, Radi L, Kaltenberg OP, Imondi AR, and Williams GM (1993) Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res 53:4534-4541. (Pubitemid 23304376)
10. Hayes DF, Van Zyl JA, Hacking A, Goedhals L, Bezwoda WR, Mailliard JA, Jones SE, Vogel CL, Berris RF, Shemano I, et al. (1995) Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 13:2556-2566.
11. Hirsimäki P, Aaltonen A, and Mäntylä E (2002) Toxicity of antiestrogens. Breast J 8:92-96.
12. Huovinen R, Wärri A, and Collan Y (1993) Mitotic activity, apoptosis and TRPM-2 mRNA expression in DMBA-induced rat mammary carcinoma treated with anti-estrogen toremifene. Int J Cancer 55:685-691. (Pubitemid 23328960)
13. Jakoby WB and Ziegler DM (1990) The enzymes of detoxication. J Biol Chem 265:20715-20718. (Pubitemid 120014066)
14. Kallio P (1986) The effect of the inverted repeat structure on the production of the cloned Bacillus amyloliquefaciens alpha-amylase. Eur J Biochem 158:491-495.
15. Kim SY, Suzuki N, Santosh Laxmi YR, Rieger R, and Shibutani S (2003) Alpha-hydroxylation of tamoxifen and toremifene by human and rat cytochrome P450 3A subfamily enzymes. Chem Res Toxicol 16:1138-1144. (Pubitemid 37163220)
16. King RS, Teitel CH, and Kadlubar FF (2000) In vitro bioactivation of N-hydroxy-2-aminoalpha-carboline. Carcinogenesis 21:1347-1354.
17. Ning B, Nowell S, Sweeney C, Ambrosone CB, Williams S, Miao X, Liang G, Lin D, Stone A, Ratnasinghe DL, et al. (2005) Common genetic polymorphisms in the 5′-flanking region of the SULT1A1 gene: haplotypes and their association with platelet enzymatic activity. Pharmacogenet Genomics 15:465-473. (Pubitemid 41017595)
18. Nowell S, Sweeney C, Winters M, Stone A, Lang NP, Hutchins LF, Kadlubar FF, and Ambrosone CB (2002) Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. J Natl Cancer Inst 94:1635-1640. (Pubitemid 35378729)
19. Raghow S, Hooshdaran MZ, Katiyar S, and Steiner MS (2002) Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res 62:1370-1376. (Pubitemid 34407794)
20. Shibutani S, Dasaradhi L, Terashima I, Banoglu E, and Duffel MW (1998a) Alphahydroxytamoxifen is a substrate of hydroxysteroid (alcohol) sulfotransferase, resulting in tamoxifen DNA adducts. Cancer Res 58:647-653. (Pubitemid 28099473)
21. Shibutani S, Ravindernath A, Terashima I, Suzuki N, Laxmi YR, Kanno Y, Suzuki M, Apak TI, Sheng JJ, and Duffel MW (2001) Mechanism of lower genotoxicity of toremifene compared with tamoxifen. Cancer Res 61:3925-3931. (Pubitemid 32720952)
22. Shibutani S, Shaw PM, Suzuki N, Dasaradhi L, Duffel MW, and Terashima I (1998b) Sulfation of alpha-hydroxytamoxifen catalyzed by human hydroxysteroid sulfotransferase results in tamoxifen-DNA adducts. Carcinogenesis 19:2007-2011. (Pubitemid 28521945)
23. Valavaara R (1990) Phase II trials with toremifene in advanced breast cancer: a review. Breast Cancer Res Treat 16 Suppl:S31-S35.
24. Weinshilboum RM (1986) Phenol sulfotransferase in humans: properties, regulation, and function. Fed Proc 45:2223-2228.
25. White IN (1999) The tamoxifen dilemma. Carcinogenesis 20:1153-1160.
26. White IN, de Matteis F, Davies A, Smith LL, Crofton-Sleigh C, Venitt S, Hewer A, and Phillips DH (1992) Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis 13:2197-2203. (Pubitemid 23022956)
27. Williams-Brown MY, Salih SM, Xu X, Veenstra TD, Saeed M, Theiler SK, Diaz-Arrastia CR, and Salama SA (2011) The effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk. J Steroid Biochem Mol Biol 126:78-86.
28. Yu X, Dhakal IB, Beggs M, Edavana VK, Williams S, Zhang X, Mercer K, Ning B, Lang NP, Kadlubar FF, et al. (2010) Functional genetic variants in the 3′-untranslated region of sulfotransferase isoform 1A1 (SULT1A1) and their effect on enzymatic activity. Toxicol Sci 118:391-403.
29. Zhang H, Varlamova O, Vargas FM, Falany CN, Leyh TS, and Varmalova O (1998) Sulfuryl transfer: the catalytic mechanism of human estrogen sulfotransferase. J Biol Chem 273: 10888-10892. (Pubitemid 28204925)